Latest news

Thumbnail

AbbVie’s venetoclax joins UK’s early access scheme

AbbVie venetoclax has been accepted onto the UK's Early Access to Medicines Scheme (EAMS), having picked up a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of chronic lymphocytic leukaemia.

24th August 2016

Thumbnail

NICE widens scope of Bayer’s Eylea

Cost regulators are now backing NHS use of Bayer's Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.

24th August 2016

Thumbnail

AZ sells antibiotics to Pfizer

AstraZeneca is selling to Pfizer rights to its late-stage small molecule antibiotics business in most markets globally outside the US, in a deal that could be worth near $1.6 billion.

24th August 2016

Thumbnail

DS Biopharma spins out Afimmune

Dublin, Ireland-based lipid science group DS Biopharma has launched a spin-out group focused solely on fibrotic conditions and pulmonary disorders.

23rd August 2016

Thumbnail

Pfizer swoops in to grap Medivation for $14bn

Following weeks of speculation Pfizer has stepped forward with a $14-billion bid for Medivation, beating Sanofi and other suitors to the finish line in a move designed to boost its oncology portfolio.

22nd August 2016

Thumbnail

EU nod for Teva’s asthma biologic

The European Commission has issued a green light for Teva's Cinqaero in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.

22nd August 2016

Thumbnail

Pfizer’s abuse-deterrent opioid bags US nod

Pfizer's Troxyca ER has been approved in the US for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

22nd August 2016

Thumbnail

EU to review Portola’s blood-thinner antidote

The group is seeking conditional approval for the drug's use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery.

22nd August 2016

Thumbnail

NHS to spend £365m on perinatal mental health

NHS England has revealed that £365 million will be streamed into specialist perinatal mental health services over the next five years to increase access to care and treatment.

22nd August 2016

Thumbnail

NICE rejects Bayer’s Nexavar for liver cancer

Bayer's Nexavar is the latest medicine currently available through the Cancer Drugs Fund that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence.

19th August 2016

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download